Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
With updated clinical guideline recommendations and changes to drug labeling in 20202022, as well as the 2021 approval of finerenonethe only new drug indicated for CKD associated with type 2 diabetes approved in this time periodit is of interest to understand how patterns of SGLT2i and GLP-1 RA use and characteristics of patients prescribed these medications in the US may have changed
Conagra Brands added a GLP-1 Friendly label to 26 of its Healthy Choice frozen meals in early 2025
[6] Ablymico was authorized for medical use in the European Union in Jully 2026
Therefore, 2026 is a transition year, while broader Medicare Part D access for weight-loss GLP-1s is scheduled to expand through CMS models beginning in 2026 and 2027
